A Research Study Looking at New Protein-based Tablets in Healthy Men - Oral Formulation IV

Phase 1 Completed 90 enrolled Novo Nordisk A/S

RandomizedCrossoverOpen-labelTreatment

Summary

This study is conducted to compare four different tablets containing the investigational medicine semaglutide at the same dose. It is done to test how semaglutide in each of the tablet versions is taken up in the body. Which treatments participants will receive is decided by chance. The study will last for about 28 weeks. The study will enroll healthy male participants.

Timeline

Start: 2024-10-15
Primary completion: 2025-07-10
Completion: 2025-08-13

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Semaglutide	Peptide	—	Subcutaneous

Indications

No indication recorded.